Table 1 Cohort characteristics
From: Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial
Characteristic | Value | Iodine seed + clip | Magnetic seed | Carbon suspension | Total (%) |
|---|---|---|---|---|---|
T stage | T1 | 27 (20.0%) | 15 (50.0%) | 12 (50.0%) | 54 (28.6%) |
T2 | 91 (67.4%) | 14 (46.7%) | 11 (45.8%) | 116 (61.4%) | |
T3 | 14 (10.4%) | 1 (3.3%) | 1 (4.2%) | 16 (8.5%) | |
T4 | 3 (2.2%) | 0 (0.0%) | 0 (0.0%) | 3 (1.6%) | |
cN stage (core-cut biopsy) | N0 | 1 (0.7%) | 5 (16.7%) | 2 (8.3%) | 8 (4.2%) |
N1 | 124 (91.9%) | 24 (80.0%) | 21 (87.5%) | 169 (89.4%) | |
N2 | 2 (1.5%) | 1 (3.3%) | 0 (0.0%) | 3 (1.6%) | |
N3 | 8 (5.9%) | 0 (0.0%) | 1 (4.2%) | 9 (4.8%) | |
ypN stage (post-surgery) | N0 | 84 (62.2%) | 12 (40.0%) | 10 (41.7%) | 106 (56.1%) |
N1 | 46 (34.1%) | 14 (46.7%) | 13 (54.2%) | 73 (38.6%) | |
N2 | 3 (2.2%) | 3 (10.0%) | 1 (4.2%) | 7 (3.7%) | |
N3 | 2 (1.5%) | 1 (3.3%) | 0 (0.0%) | 3 (1.6%) | |
M stage | M0 | 133 (98.5%) | 30 (100.0%) | 24 (100.0%) | 187 (98.9%) |
M1 | 2 (1.5%) | 0 (0.0%) | 0 (0.0%) | 2 (1.1%) | |
Tumour type | NST | 128 (94.8%) | 22 (73.3%) | 23 (95.8%) | 173 (91.5%) |
Lobular others | 2 (1.5%) | 6 (20.0%) | 1 (4.2%) | 9 (4.8%) | |
5 (3.7%) | 2 (6.7%) | 0 (0.0%) | 7 (3.7%) | ||
Grading | G1 | 2 (1.5%) | 8 (26.7%) | 5 (20.8%) | 15 (7.9%) |
G2 | 50 (37.0%) | 15 (50.0%) | 15 (62.5%) | 80 (42.3%) | |
G3 | 83 (61.5%) | 7 (23.3%) | 4 (16.7%) | 94 (49.7%) | |
Type of breast surgery | MAE | 58 (43.0%) | 7 (23.3%) | 8 (33.3%) | 73 (38.6%) |
BCS | 77 (57.0%) | 23 (76.7%) | 16 (66.7%) | 116 (61.4%) | |
135 (100.0%) | 30 (100.0%) | 24 (100.0%) | 189 (100.0%) |